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Tuberculosis (TB) is a major infectious disease killing nearly two million people, mostly in
developing countries, every year. The increasing incidence of resistance of Mycobacterium
tuberculosis strains to the most-effective (first-line) anti-TB drugs is a major factor contrib-
uting to the current TB epidemic. Drug-resistant strains have evolved mainly due to incomplete
or improper treatment of TB patients. Resistance of M. tuberculosis to anti-TB drugs is caused
by chromosomal mutations in genes encoding drug targets. Multidrug-resistant (resistant at
least to rifampin and isoniazid) strains of M. tuberculosis (MDR-TB) evolve due to sequential
accumulation of mutations in target genes. Emergence and spreading of MDR-TB strains is
hampering efforts for the control and management of TB. The MDR-TB is also threatening
World Health Organization’s target of tuberculosis elimination by 2050. Proper management
of MDR-TB relies on early recognition of such patients. Several diagnostic methods, both
phenotypic and molecular, have been developed recently for rapid identification of MDR-TB
strains from suspected patients and some are also suitable for resource-poor countries. Once
identified, successful treatment of MDR-TB requires therapy with several effective drugs
some of which are highly toxic, less efficacious and expensive. Minimum treatment duration
of 18e24 months is also long, making it difficult for health care providers to ensure adherence
to treatment. Successful treatment has been achieved by supervised therapy with appropriate
drugs at institutions equipped with facilities for culture, drug susceptibility testing of MDR-TB
strains to second-line drugs and regular monitoring of patients for adverse drug reactions and
bacteriological and clinical improvement.
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The morbidity and mortality associated with tuberculosis
(TB) continue to remain high despite intense worldwide
efforts. Two major factors that are sustaining the current
TB epidemic include expanding human immunodeficiency
virus (HIV) infection and its association with active TB
disease and increasing resistance of Mycobacterium
tuberculosis strains to the most-effective (first-line) anti-
TB drugs.1 Other factors that have also contributed include
population expansion, poor case detection and cure rates in
impoverished countries, active transmission in over-
crowded hospitals, prisons and other public places, immi-
gration from high incidence countries, drug abuse and
homelessness. Active disease patients with sputum-positive
pulmonary TB are the main source of infection in commu-
nities. Although an effective immune response arrests
multiplication of M. tuberculosis soon after infection in
majority of cases, only w10% individuals eradicate the
pathogen completely while w90% only succeed in
containment of infection and thus remain latently infec-
ted.2 The World Health Organization (WHO) has estimated
that nearly a third of the world population is now infected
with M. tuberculosis and 5e10% of the infected individuals
will develop active TB disease during their lifetime.
However, the risk of developing active disease is 5e15%
every year and lifetime risk is w50% in HIV-coinfected
individuals.3
In 2006, 9.2 million new active disease cases (4.1 million
being sputum smear-positive) corresponding to an esti-
mated incidence of 139 per 100,000 population occurred
throughout the world.1 Only half of these cases were
actually reported while the rest were based on assessments
of effectiveness of surveillance systems. The highest inci-
dence rate (363 per 100,000 population) was recorded for
the African region, mainly due to high prevalence of HIV
infection. The 22 high burden (11 Asian, 9 African, 1 South
American and 1 East European) countries accounted for
>84% of all active TB cases worldwide. The lowest inci-
dence rates (<20 cases per 100,000) were recorded for
some developed, rich countries. Nearly 700,000 (7.6%) of9.2 million TB patients were coinfected with HIV and w0.5
million cases of multidrug-resistant TB (MDR-TB, defined as
infection with M. tuberculosis strains resistant at least to
rifampin, RIF and isoniazid, INH) occurred in 2006. Globally,
the total prevalent TB cases in 2006 were 14.4 million that
resulted in 1.7 million deaths (w95% occurring in devel-
oping countries).1
Emergence of drug-resistant TB
The problem of drug-resistant TB is not new. In 1948, the
British Medical Research Council reported that the
mortality rates in pulmonary TB patients treated or not
treated with streptomycin (SM) were the same, however,
most patients in the treated group had died of relapse with
SM-resistant strains.4 Standard short-course chemotherapy
with multiple drugs developed in 1960s and 1970s effec-
tively kills all bacilli localized in different environments
(e.g. pulmonary cavities, pus, solid caseous material,
immune cells) including naturally occurring monodrug-
resistant strains (as they are killed by other drugs) and
controls the emergence of multidrug-resistant strains.5,6
Successful treatment of fully susceptible TB depends on
combination of drugs and duration of therapy, cost, and
drug’s side effects. Conversion of culture-positive to
culture-negative sputum within 2 months and subsequent
clearing of filtrates on chest radiograph are positive signs
while positive sputum cultures after 4 months of multidrug
therapy indicate treatment failure.7 Treatment failure is
due to multiple factors (including, among other, incom-
plete or inappropriate therapy) and results in persistence of
the disease mainly due to emergence of drug resistance
(acquired resistance). Primary resistance occurs when the
resulting M. tuberculosis strain is transmitted to a new
host, as it causes TB that is already resistant to the indi-
cated drug(s).1,2 Major factors associated with drug resis-
tance development include presence of cavitation together
with smear-positive sputum and positive sputum culture,
non-adherence to therapy due to multiple factors (such as
cost of drugs, long duration and multiple drug combination
used in treatment regimens and drug related adverse
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equate resources in high burden countries, and prior history
of treatment with anti-TB drugs.1,7e9 The M. tuberculosis
W/Beijing genotype has strong association with MDR
phenotype.10 Simultaneous treatment of HIV-TB coinfection
may lead to malabsorption and suboptimal therapeutic
blood levels of RIF and INH (despite adherence to therapy)
that facilitate the development of drug-resistant TB and
MDR-TB.3,9 The malabsorption of anti-TB drugs may also
occur in patients with some other underlying diseases.11,12
Global epidemiology of MDR-TB
Four successive reports of Global Projects on Antitubercu-
losis Drug Resistance Surveillance sponsored by WHO were
published in 1997, 2001, 2006 and 2008. The latest report
collected drug susceptibility testing (DST) data for INH, RIF,
SM and ethambutol (EMB) from 93 settings in 81 countries
during 2002e2007 and showed that resistance to at least one
anti-TB drug (any resistance) among new TB cases was lower
(varying from 0% to 56%) than in previously treated TB
patients (varying from 0% to 86%).9 The worldwide average
for any resistance, INH resistance and MDR among all TB
cases were estimated to be 20%, 13.3% and 5.3%, respec-
tively. The rates of resistance for any drug, INHandMDRwere
higher in retreatment versus new TB cases. The data showed
that 489139 cases of MDR-TB occurred in 2006 representing
4.8% of all TB cases. The highest percentage of MDR-TB cases
were estimated for countries of Eastern Europe (19.2%) fol-
lowed by Western Pacific region (7%) and Southeast Asia
(4.3%). The data also showed that compared to the previous
report,13 the burden of MDR-TB cases declined in USA and
Hong Kong, remained stable in several European countries
and increased in some developing countries.9
The MDR-TB is a major threat to global public health as it
is difficult to treat and often results in relapse or treatment
failure.14,15 It is also a risk factor for the emergence of XDR-Table 1 Important genes (and their encoded products) of M. tub
line anti-TB drugs.
Anti-TB drug(s) Gene target Encoded protein
or RNA product
RIF rpoB b-Subunit of RNA polym
INH katG Catalase/peroxidase
INH/ETH inhA Enoyl-acyl carrier
protein reductase
PZA pncA Pyrazinamidase
EMB embB Arabinosyltransferase
EMB embA Arabinosyltransferase
EMB iniA Isoniazid-inducible gene
SM rrs 16S rRNA
SM rpsL Ribosomal Protein S12
FQs gyrA A subunit of DNA gyrase
FQs gyrB B subunit of DNA gyrase
KAN/AMI rrs 16S rRNA
CAP/VIO rrs 16S rRNA
CAP/VIO tlyA Cytotoxin/haemolysin h
RIF, rifampin; INH, isoniazid; ETH, ethionamide; PZA, pyrazinamid
(ciprofloxacin, ofloxacin, levofloxacin); KAN, kanamycin; AMI, amikacTB (defined as infection with MDR-TB strains additionally
resistant either to a new-generation fluoroquinolone and an
injectable agent or to three of the six main classes of
second-line drugs).16 In 2006, nearly 10% of all MDR-TB
cases in the former Soviet Union countries (ranging from 4%
in Armenia to 24% in Estonia) were XDR-TB.9 In South Africa,
996 of 17615 (5.6%) of MDR-TB cases were also XDR-TB.
Although 50 countries have already reported one or more
cases of XDR-TB, there is no information for several other
countries that have a high incidence of MDR-TB.17 The
emergence of XDR-TB is extremely worrisome as it is more
difficult to treat than MDR-TB in developed countries and is
virtually untreatable in developing countries. An outbreak
of XDR-TB in South Africa was highly lethal.18
Anti-TB drugs: mechanism of action and
resistance
A better understanding of drug resistance mechanisms in
M. tuberculosis is crucial for the development of rapid
methods for drug resistance detection and new anti-TB
drugs to treat MDR-TB/XDR-TB patients. Early molecular
studies identified katG (encoding catalaseeperoxidase) and
rpoB (encoding b-subunit of RNA polymerase) genes as
major targets conferring resistance of M. tuberculosis to
INH and RIF, respectively.19,20 The current knowledge of the
genes and their target regions involved in mediating resis-
tance of M. tuberculosis to important anti-TB drugs is
summarized in Table 1.
Isoniazid (INH), a pro-drug, has the highest activity (MIC
<0.05 mg/ml) against actively dividing M. tuberculosis.19 It
is activated by catalaseeperoxidase encoded by katG.
Activated INH mainly targets NADH-specific enoyl-acyl
carrier protein (ACP) reductase (encoded by inhA) and b-
ketoacyl ACP synthase (encoded by kasA) involved in
mycolic acid synthesis. Depletion of mycolic acids results in
bacterial killing.19,21erculosis conferring resistance to first-line and some second-
Major target region in
encoded product
Level of
resistance
erase 81-bp HSR High
Entire gene High
Upstream regulatory region Low
Several codons High
Several codons High
Several codons High
Few codons High
Several nucleotides Low
Codons 43 and 48 High
Few codons High
Few codons High
Position 1401 or 1484 High
Position 1401 or 1484 High
omologue Several codons High
e; EMB, ethambutol; SM, streptomycin; FQs, fluoroquinolones
in; CAP, capreomycin; VIO, viomycin; and HSR, hot-spot region.
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a variety of mutations (insertions, deletions and point
mutations) in several genes. The main targets include katG
and the regulatory and coding region of inhA.19,21,22
Mutations in other genes are either compensatory resulting
from the loss of catalaseeperoxidase activity or have
a minor role.23 Despite the complexity, high- and low-level
resistance to INH is mainly due to mutations within the
katG and inhA regulatory region.19,21e24 The katG gene
mutations occur frequently between codons 138 and 328,
particularly at codon 315 (katG315). The mutations in inhA
regulatory region occur mostly at positions 15 and 8
(relative to mabA translational start site). The frequency
of katG315 (w50e95%) and inhA regulatory region (w6e
30%) mutations vary considerably depending upon the
ethnicity of the infected TB patient/geographical location
where M. tuberculosis strain is isolated (Table 2).24e28
Some INH-resistant strains do not have an identifiable
mutation implying that additional targets are involved.23,24
Rifampin (RIF), a lipophilic rifamycin derivative, binds to
b-subunit of RNA polymerase (encoded by rpoB) and inhibits
RNA transcription and consequently, protein synthesis in
M. tuberculosis.20,23 Mutations in rpoB gene confer RIF
resistance by affecting drug binding. Monoresistance to RIF
is rare except in HIV-coinfected patients and RIF resistance
is often a surrogate marker for MDR-TB sincew85e90% RIF-
resistant strains are also resistant to INH.3,20,29e32 Nearly
90e95% of RIF-resistant strains carry missense mutations or
small in-frame insertions/deletions within an 81-bp hot-
spot region (HSR) mainly involving rpoB codons 531, 526 and
516 (Table 2).20,30e34 Resistance in w5e10% RIF-resistant
isolates is due to mutations in N-terminal or other regions of
the rpoB gene or due to some unknown mechanism.20,35,36
Specific mutations in HSR and N-terminal region also show
variations depending upon the ethnicity of TB patient/
geographical location where M. tuberculosis strain is iso-
lated.30e34,36
Missense mutations at rpoB codon 511, 518 or 522 cause
low-level while those at codon 516, 526 or 531 cause
high-level RIF resistance.35,37 Also, a relationship exists
between specific rpoB mutations and cross-resistance of
M. tuberculosis isolates to other rifamycins. Isolates with
mutations at codon 511 or 533 exhibit low-level RIF
resistance but remain susceptible to rifabutin (RBU) while
those with mutations at codon 514, 515, 516, 522 or 533
become RIF-resistant but remain susceptible or exhibitTable 2 Frequency of mutations in main target region and
conferring resistance to anti-TB drugs in M. tuberculosis.
Anti-TB agent(s) Gene target Main target region
RIF rpoB 81-bp HSR
INH katG Entire gene
INH/ETH inhA Regulatory region
PZA pncA Several codons
EMB embB Several codons
SM rpsL Codons 43 and 48
RIF, rifampin; INH, isoniazid; ETH, ethionamide; PZA, pyrazinamide;
a Nucleotide situated relative to the start of mabA open reading fralow-level resistance to RBU. However, M. tuberculosis
isolates with rpoB mutations in N-terminal region or at
codon 513, 526 or 531 exhibit high-level resistance to both
RIF and RBU.37,38 Thus, RBU may be used as a second-line
drug for the treatment of some patients infected with RIF-
resistant strains carrying specific rpoB mutations.
Pyrazinamide (PZA), a pro-drug, is highly effective
against semidormant bacilli in acidic environment (like
macrophages).22,23 The PZA is activated by pyrazinamidase
encoded by pncA gene to pyrazinoic acid which, by
lowering intracellular pH, inactivates a vital fatty acid
synthase. The PZA is highly specific against M. tuberculosis,
other mycobacteria are intrinsically resistant to PZA due to
lack of an efficient pyrazinamidase. Similar to INH, most
PZA-resistant M. tuberculosis strains also contain mutations
in pncA gene that activates the pro-drug.39,40 Nearly
20e30% of PZA-resistant M. tuberculosis strains contain
wild-type pncA, suggesting the existence of other resistance
conferring mechanism(s).23,39,40
Ethambutol (EMB) is now used in place of SM in combi-
nation therapy with INH, RIF and PZA since resistance of
M. tuberculosis strains to EMB is much less compared to
SM.1,9,13 The molecular basis of resistance to EMB is not
fully defined. The EMB mainly targets enzymes partici-
pating in synthesis and polymerization of cell wall arabinan,
and interacts with three homologous, membrane associated
arabinosyltransferases encoded by embCeembAeembB
genes.41 It also affects proteins encoded by isoniazid-
inducible genes like iniA and acyl carrier proteins and other
proteins regulating their expression.41,42 Mutations in
embB, particularly at embB306, embB406 and embB497
occur more frequently and confer resistance to EMB.43,44
The frequency of embB306 mutations also varies (20e70%)
in EMB-resistant strains from different geographical loca-
tions (Table 2).41,42,45
Streptomycin (SM) is nearly as effective as EMB,
however, several factors have discouraged its use in more
recent times. Oral formulations in multidrug regimens are
not feasible requiring frequent patient’s visit to health care
facilities. Globally, highest level of resistance to an anti-TB
drug is also observed for SM.9,13 The SM may be used as
a first-line or second-line drug for treating patients with
failing therapy or MDR-TB provided the M. tuberculosis
strain is susceptible to SM.7 The SM binds to a ribosomal
protein and 16S rRNA (encoded by rpsL and rrs, respec-
tively) causing misreading of mRNA and faulty proteinmost commonly mutated codon/nucleotide in target gene
Relative frequency
in resistant strains
Most common mutation at
Codon/nucleotide Frequency
90e95% Codon 531 30e75%
50e95% Codon 315 50e95%
6e30% Nucleotide (-)15a 6e30%
62e97% No dominant mutation
47e89% Codon 306 20e70%
40e95% Codon 43 40e90%
EMB, ethambutol; SM, streptomycin; and HSR, hot-spot region.
me of mabA-inhA operon.
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rrs gene, nearly 30% of SM-resistant M. tuberculosis isolates
contain mutations in the rrs gene.46,47 The remaining SM-
resistant M. tuberculosis strains either contain mutations in
rpsL (at rpsL43 or rpsL88) or in other genes.23,46,47
Other aminoglycosides, kanamycin (KAN) and amikacin
(AMI) also inhibit protein synthesis (peptide chain elonga-
tion) in M. tuberculosis and are used as second-line
injectable drugs for actively dividing bacteria.2,7 Resistance
to KAN and AMI is mainly associated with rrs mutations.
Although cross-resistance between KAN and AMI has been
reported, cross-resistance between SM and either KAN or
AMI is not reported, hence KAN/AMI may be used for SM-
resistant strains.48 However, cross-resistance between
KAN/AMI and other injectable agents such as capreomycin
(CAP) and viomycin (VIO) (cyclic peptides) has been
described. The rrs mutation A1401 G is associated with
high-level KAN and AMI resistance but usually causes low-
level resistance to CAP and no resistance to VIO while
C1402 T is associated with high-level CAP and VIO resistance
but usually causes low-level resistance to KAN and no
resistance to AMI in M. tuberculosis.48 However, rrs muta-
tion G1484 T is associated with high-level resistance to CAP,
VIO, KAN and AMI.48 Another mechanism conferring resis-
tance to CAP and VIO involves mutations in the tlyA gene.49
Fluoroquinolones (FQs) such as ofloxacin (OFX) and lev-
ofloxacin (LFX) are important second-line drugs for treating
MDR-TB.1,9,15 The new-generation FQs (moxifloxacin, MFX
and gatifloxacin, GFX) have excellent bactericidal activity
against M. tuberculosis.50 The FQs inactivate DNA gyrase
(composed of two A and two B subunits encoded by gyrA
and gyrB genes, respectively) and inhibit DNA replication.51
In M. tuberculosis, resistance to FQs is mainly associated
with mutations at codons 90, 91 and 94 of gyrA gene.31,51e53
Some FQ-resistant M. tuberculosis strains contain muta-
tions at gyrB464 or gyrB495.52
Ethionamide (ETH), a structural analog of INH, is used as
a second-line drug for MDR-TB and shares the target with
INH. Similar to INH, ETH is also a pro-drug, however, it is
activated by a monooxygenase (encoded by ethA).54 The
ethA catalyses a two step activation of ETH to its active
form (4-ethyl-4-amidopyridine). Similar to INH and PZA,
majority of ETH-resistant M. tuberculosis strains contain
mutations in ethA that abolish activation of pro-drug.54
Similar to INH, the main cellular target of activated ETH is
inhA and mutations in inhA regulatory region that are
associated with INH resistance also cause cross-resistance
to ETH.23,54Diagnosis of active TB disease
The diagnosis of active disease (including pulmonary as well
as extrapulmonary TB) is usually based on clinical suspicion,
chest radiographs, smears for acid-fast bacilli (AFB), solid
and liquid culture and, more recently, hybridization- and
PCR amplification-based detection ofM. tuberculosis nucleic
acid in clinical specimens. A brief outline for the diagnosis of
active TB disease is described here. Several review articles
are available for a more detailed description.6,55e57
Microscopic examination of smears for acid-fast bacilli
for all clinical specimens is a rapid and inexpensive test,however, it is positive in only 34e80% of expectorated
sputum samples and is often negative in HIV-coinfected TB
patients due to atypical presentation.1,55 The sensitivity for
non-sputum samples is even less. Also, the test does not
differentiate TB from infections caused by non-tuberculous
mycobacteria (NTM). The gold standard for TB diagnosis is
culture of M. tuberculosis. The culture also allows species-
specific identification, DST to guide therapy and finger-
printing of isolates during epidemics. Culture on solid media
takes 4e6 weeks while liquid media-based culture systems
yield faster (7e12 days) growth of M. tuberculosis.6 Phage-
based assays developed more recently offer rapid detection
of M. tuberculosis in resource-poor settings.56
Molecular methods have provided rapid diagnosis of TB in
smear-negativespecimensparticularlywhentheorganismcan
notbegrownincultureandalsotorapidlydifferentiateculture-
grownM. tuberculosis from NTM.6,57 Twomolecular tests are
also approved by FDA for respiratory specimens.57 In-house
developed PCR assays vary in their choice of amplification
target, detection platforms, sensitivity and reliability of the
results.6,57,58 Two reverse hybridization-based assays allow
identificationofM.tuberculosisandseveralNTMspecies,both
in cultured isolates and clinical specimens.59e61 However,
molecular testshavenotbeenable to replacemicroscopyand
culture, but are rather used to confirm the presence of
M.tuberculosis inpositivesputumandnon-sputumsmears.
Diagnosis of MDR-TB
Rapid detection of drug resistance of M. tuberculosis and
MDR-TB strains ensures effective treatment of TB patients
and limits further development of resistance to additional
drugs. The CDC strongly encourages reporting of DST
results within 30 days of specimen collection.7 Recent
developments have considerably improved the diagnosis of
drug-resistant TB and MDR-TB by both, conventional
(phenotypic) and molecular (genotypic) methods.
Conventional (phenotypic) methods
Conventional (phenotypic) DST methods require culture
and detect the growth of M. tuberculosis in the presence of
anti-TB drugs by one of three (proportion, resistance ratio
or absolute concentration) methods on solid media.6 The
broth-based semiautomated, radiometric BACTEC 460 TB
system (Becton Dickinson) is regarded as the gold standard
for culture and DST of M. tuberculosis to both first- and
second-line anti-TB drugs.62,63 The 460 TB system reports
DST results within 4e12 days from primary cultures, while
solid media-based methods require nearly 3 weeks. More
recently nonradioactive, fully automated liquid culture
systems have been developed for culture and DST of
M. tuberculosis.63e65 Of these, BACTEC MGIT 960 TB system
has been more extensively used and is considered equiva-
lent to BACTEC 460 TB system in recovery and DST of
M. tuberculosis.63e65 Susceptibility cut-off values for both,
first-line and second-line anti-TB drugs have been deter-
mined.6,62e65 Although MGIT 960 system may be used
directly on sputum samples, additional time and labor is
needed for identification of M. tuberculosis. The auto-
mated liquid culture systems are expensive for developing
1782 S. Ahmad, E. Mokaddascountries. Other cost-effective methods have been devel-
oped for resource-poor settings.
The liquid media-based microscopic observation drug
susceptibility (MODS) test is a low-cost, rapid and direct
assay for simultaneous detection and DST of M. tuberculosis
in sputum specimens. The test requires skills similar to those
for smear microscopy, detects M. tuberculosis-specific
cording growth and results are available within 2 weeks in
most cases.66e68 The limitation of MODS test are indirect
identification of M. tuberculosis and requirement for
frequent (if not daily) microscopic observations. The
colorimetric methods are another alternative for detecting
drug-resistant M. tuberculosis strains.69 They are based on
reduction of redox indicators that are added to culture
medium during in vitro growth of M. tuberculosis. The
tetrazolium salt-based assay utilizes 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) which is
yellow in color in its oxidized form but, is reduced to blue/
purple colored compound during growth of M. tuberculosis.
This method has been evaluated for direct detection of RIF
resistance on smear-positive sputum samples with excellent
results.70 The resazurin microtitre assay is based on oxida-
tion of resazurin by a growing culture of M. tuberculosis in
the presence of anti-TB drugs.71 The nitrate reductase assay
depends on ability of viable M. tuberculosis to reduce
nitrate to nitrite and the results are usually available within
10 days.72 This simple assay provides rapid, accurate and
cost-effective detection of MDR-TB and has performed well
with smear-positive sputum samples.69,72 Unlike MODS,
a limitation of nitrate reductase assay is the possibility of
false-positive detection of M. tuberculosis due to growth of
other organisms.
The phage-based assays use mycobacteriophages to
infect live M. tuberculosis in the absence and presence of
anti-TB drugs and detect the bacilli using either the phage
amplification assay or production of light.56 The method
based on detection of light uses luciferase reporter myco-
bacteriophages (e.g. phAE142). Viable M. tuberculosis
growing in presence of anti-TB drug and infected with
phage phAE142 emit light in the presence of luciferin and
are identified as drug-resistant strains.73 The FAST Plaque
TB-Response (Biotec Laboratories Ltd.) assay detects drug
resistance of M. tuberculosis directly in sputum specimens.
The method provides rapid (within 2 days) and accurate
results when compared with the proportion method and the
BACTEC radiometric method.74
Molecular (genotypic) methods
Molecular (genotypic) DST methods detect resistance asso-
ciated mutations in target genes of M. tuberculosis, provide
results within 1e2 days and can be performed directly on
smear-positive sputum and other clinical samples.57,75,76
Although genotypic methods have been developed for all
first-line and many second-line drugs, detection of RIF
resistance is more practical and a priority, since 90e95%
RIF-resistant strains contain mutations in a small (81-bp)
region (HSR) of a single (rpoB) gene and RIF resistance is
a surrogate marker for MDR-TB.20,75e77 For other anti-TB
drugs, the sensitivity of resistance detection varies more
widely due to the number of gene loci involved and the sheer
diversity of mutations.23 Still, drug-resistantM. tuberculosisstrains isolated from TB patients of different ethnic back-
ground or from different geographical locations may exhibit
few dominant mutations.26 Hence, prior knowledge about
the nature and frequency of resistance conferring mutations
is critical to develop region-specific molecular diagnostic
methods. Alternatively, assays targeting entire gene or
multiple gene loci in a single test may be utilized.40,78e80
Several methods have been developed and evaluated for the
detection of resistance conferring mutations in MDR-TB
strains.
The PCR-restriction fragment length polymorphism
(PCR-RFLP) analysis is a simple, rapid and inexpensive
method to detect polymorphism at a single or few codons
that are mutated in drug-resistant strains.81e83 The PCR-
RFLP has been mostly used for the detection of katG315 and
embB306 mutations for rapid detection of INH and EMB
resistance, respectively.45,83
The DNA sequencing provides unambiguous detection of
mutations. Results of resistance detection by other methods
have traditionally been confirmed by DNA sequencing of
target gene region/codon. Direct DNA sequencing of gene
target is most practical if majority of drug-resistant strains
contain mutations in a limited region of a single target gene.
This is particularly true for RIF (>90% RIF-resistant strains
contain mutations in HSR of rpoB gene) and PZA (due to
small size of pncA gene).20,39 Also, most INH-resistant
strains from some geographical locations contain mutations
at katG315.26,83 Thus, targeted DNA sequencing has been
applied for the detection of mutations conferring resis-
tance to RIF, INH and PZA. The DNA sequencing is still
considered as impractical in most developing countries
for analyzing large number of specimens. However, recent
technological advances may lead to rapid, accurate and
cost-effective analysis of DNA sequences for detection of
MDR M. tuberculosis strains.84
Real-time PCR assays have also been developed for rapid
diagnosis of MDR-TB in smear-positive sputum specimens by
detecting mutations in rpoB, katG and regulatory region of
inhA gene.85,86 A commercial real-time PCR-based assay has
now become available for RIF resistance detection in both
smear-positive and smear-negative sputum samples (Xpert
MTB, Cepheid). Since RIF resistance is a surrogate marker
for MDR-TB, the positive test will also detectw90% of MDR-
TB strains from most geographical locations.
The reverse hybridization-based line probe assays
(macroarrays) and microarray-based assays have also been
developed for detection of MDR-TB strains directly in clin-
ical specimens. There are two commercially available DNA
macroarray assays for detection of MDR M. tuberculosis.
The INNO-LiPA Rif. TB assay (Innogenetics) detects muta-
tions in HSR of rpoB gene.75,87 Since RIF resistance is
a surrogate marker for MDR-TB, the positive result also
predicts MDR status of w90% M. tuberculosis strains. The
GenoType MTBDRplus (Hain Lifesciences) assay detects
MDR-TB by simultaneously detecting mutations in HSR of
rpoB gene for RIF resistance and mutations at katG315 and
inhA regulatory region for INH resistance.76,88,89 Although
expensive, these assays have performed satisfactorily in
high incidence countries for detection of MDR M. tubercu-
losis in clinical samples within one working day.87,89
Recently, line probe assays have also been developed for
detecting resistance of M. tuberculosis to PZA and FQs.40,90
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have been tested for detecting resistance to RIF, INH, and
EMB by using several probes simultaneously.80,91 Some
microarray-based assays are now commercially available
(Autogenomics).
Treatment and management of TB and MDR-TB
The drugs currently being used for the treatment of TB and
MDR-TB are listed in Table 3. First-line drugs (INH, RIF, PZA
and EMB) are mainly bactericidal, highly efficacious and
relatively less toxic. Second-line drugs are mainly bacte-
riostatic, less effective, costly and have more drug-
associated adverse effects.7 These include aminoglycosides
(kanamycin, KAN; amikacin, AMI and streptomycin, SM), the
polypeptides (capreomycin, CAP and viomycin, VIO), the
thioamides (ethionamide, ETH and prothionamide, PTH),
several fluoroquinolones (FQs) (such as ofloxacin, OFX;
levofloxacin, LFX; moxifloxacin, MFX; and gatifloxacin,
GFX), para-amino salicylic acid (PAS) and D-cycloserine
(CS).7,9 The SM is now regarded as a second-line drug due to
higher rates of resistance of M. tuberculosis isolates to SM
and the availability of more effective anti-TB drugs.7
Rifabutin (RBU) may be used as a second-line drug for some
RIF-resistant M. tuberculosis strains. The new-generation
FQs (MFX and GFX) are bactericidal and are being consid-
ered as first-line agents.50,92 Some other drugs that are not
M. tuberculosis-specific but exhibit significant in vitro and/
or in vivo activity are also being used for the treatment
of MDR-TB and XDR-TB. These third-line or reinforcing
agents (Table 3) include clarithromycin (CLR), clofazimine
(CFZ), amoxicillin-clavulanic acid (AMX-CLV) and linezolid
(LZD).17,93,94Table 3 Some important anti-tubercular drugs and their mode
Drug(s) Chemical description Route Cl
INH Nicotinic acid hydrazide Oral Fi
RIF Rifamycin derivative Oral Fi
PZA Nicotinamide derivative Oral Fi
EMB Ethylene diimino di-1-butanol Oral Fi
RBU Rifamycin derivative Oral Se
SM Aminoglycoside Injectable Se
KAN/AMI Aminoglycoside Injectable Se
CAP/VIO Cyclic peptide Injectable Se
CIP/OFX Fluoroquinolone Oral Se
LFX Fluoroquinolone Oral Se
MFX/GFX Newer fluoroquinolone Oral Se
ETH/PTH Isonicotinic acid derivative Oral Se
PAS Para-amino salicylic acid Oral Se
CS D-Cycloserine Oral Se
TAC Thiacetazone Oral Se
CLR Erythromycin derivative Oral Th
AMX-CLA b-lactam with b-lactamase inhibitor Oral Th
CFZ Iminopherazine derivative Oral Th
LZD Oxazolidinone derivative Oral Th
INH, isoniazid; RIF, rifampin; PZA, pyrazinamide; EMB, ethambutol; R
CAP, capreomycin; VIO, viomycin; CIP, ciprofloxacin; OFX, ofloxacin; L
amino salicylic acid; CS, D-cycloserine; TAC, thiacetazone; CLR, cla
ulanate b-lacatamase inhibitor; CFZ, clofazimine; LZD, linezolid.The first-line drugs, INH and RIF are the back bone of
treatment for TB. If resistance develops to either of the two
drugs, the patients can still be successfully managed with
the available drugs, although treatment duration is
increased, particularly for infections caused by RIF-resistant
strains.95 Among clinical M. tuberculosis isolates, mono-
resistance to INH is common while monoresistance to RIF
occurs infrequently except in HIV-coinfected TB patients
and is regarded as a surrogate marker for MDR-TB.9,20
Although infections caused by INH monoresistant strains can
be effectively managed with available first-line and other
drugs, both treatment duration and treatment failure are
slightly higher compared to TB caused by fully susceptible
strains.7,95 However, infections caused by RIF-resistant
M. tuberculosis strains have poor prognosis compared to
drug-susceptible TB mainly because RIF is most-effective
drug against persisting bacilli that are mainly responsible for
clinical relapse. Increasing treatment duration to 12 months
with anti-TB drugs results in better prognosis.7,95
If M. tuberculosis strain has become resistant to both,
INH and RIF (MDR-TB), treatment is much more difficult,
particularly in HIV-TB coinfected patients. The treatment
for MDR-TB requires more extensive usage of second-line
drugs and lasts for nearly two years. The treatment for
MDR-TB is w100 times more costly, many of the second-
line drugs are highly toxic and more likely to cause
adverse drug reactions, undesirable interactions occur
with antiretroviral drugs in HIV-coinfected TB patients and
much higher relapse and mortality rates are observed
compared to drug-susceptible TB.7,95e97 Although initial
outbreaks of MDR-TB resulted in very high mortality
rates, subsequent advances in diagnosis and optimization
of therapy regimens in industrialized countries greatlyof action.
ass Mode of action Biological process inhibited
rst-line Bactericidal Mycolic acid synthesis
rst-line Bactericidal Protein synthesis
rst-line Bactericidal Unknown
rst-line Bacteriostatic Lipid/cell wall synthesis
cond-line Bactericidal Protein synthesis
cond-line Bactericidal Protein synthesis
cond-line Bactericidal Protein synthesis
cond-line Bactericidal Protein synthesis
cond-line Bacteriostatic DNA replication
cond-line Likely bactericidal DNA replication
cond-line Bactericidal DNA replication
cond-line Bacteriostatic Mycolic acid synthesis
cond-line Bacteriostatic Unknown
cond-line Bacteriostatic Cell wall synthesis
cond-line Bacteriostatic Mycolic acid synthesis
ird-line Bactericidal Protein synthesis
ird-line Bactericidal Cell wall synthesis
ird-line Bacteriostatic Cell membrane function
ird-line Bactericidal Protein synthesis
BU, rifabutin; SM, streptomycin; KAN, kanamycin; AMI, amikacin;
FX, levofloxacin, MFX, moxifloxacin; GFX, gatifloxacin; PAS, para-
rithromycin; AMX-CLA, amoxicillin b-lactam antibiotic with clav-
1784 S. Ahmad, E. Mokaddasimproved clinical outcome, even in HIV-positive TB
patients receiving antiretroviral drugs.98e100 Recent
developments in rapid diagnosis of MDR-TB, prompt insti-
tution of aggressive therapy with several active drugs, close
radiological and bacteriological (for sputum smear and
culture) monitoring of patients have resulted in further
improvement in clinical outcome and lower mortality rates
in both HIV-negative and HIV-coinfected TB patients.101e103
The suggested therapy regimens and average duration of
treatment for infections with MDR M. tuberculosis strains
resistant to different combinations of anti-TB drugs are
listed in Table 4.
Current guidelines for successful management of
patients require treating centers to be equipped with rapid
diagnostic procedures for MDR-TB detection and universal
DST for first- and second-line drugs.66,104e106 Due to poor
prognosis, rapid diagnosis of MDR-TB is even more critical in
HIV-coinfected individuals, however, conventional diag-
nostic methods lack sensitivity due to lower sputum-smear
positivity and atypical presentation.3,104,106 Molecular
methods, if available, should be used for rapid detection
and DST to guide therapy. The DST profile is crucial for
tailoring individualized treatment regimens (ITRs) and for
monitoring response to treatment during therapy for MDR-
TB. Studies have shown that ITRs guided by DST results have
better clinical outcome even in developing coun-
tries.105,107,108 In developing countries that lack universal
culture and DST facilities, epidemiological information,
prior treatment history and poor response to current TB
treatment may help in the diagnosis of MDR-TB. In some
resource-poor countries with limited infrastructure, culture
and DST are being performed by a regional/national labo-
ratory.109 It has also been observed that a proactive
approach to identify MDR-TB cases optimizes therapy with
more aggressive initial drug regimens. Early initiation of
therapy regimens containing several (4e6 or even more)
drugs, not previously taken and thus more likely to be
effective, has a more favorable outcome for MDR-TB while
delaying therapy results in higher mortality rates.7,97,110Table 4 Potential regimens for the treatment of patients with
Different patterns
of resistance
to anti-TB drugs
Appropriate therapy
regimens
None INH, RIF, PZA, EMB
INH RIF, PZA, EMB and/or FQ
RIF INH, PZA, EMB, SM FQ
INH, RIF PZA, EMB, FQ, INJ SLD
INH, RIF, EMB PZA, FQ, INJþ SLD
INH, RIF, PZA EMB, FQ, INJþ SLD
INH, RIF, PZA, EMB FQ, INJþ SLD
INH, RIF, PZA, EMB, FQ INJþ SLDþ TLD
INH, RIF, PZA, EMB, INJ FQþ INJaþ SLDþ TLD
INH, RIF, PZA, EMB, FQ, INJ INJaþ SLDþ TLD
INH, isoniazid; RIF, rifampin; PZA, pyrazinamide; EMB, ethambutol; S
moxifloxacin or gatifloxacin; INJ, injectable agents like SM or kanamyc
like rifabutin, ethionamide, prothionamide, para-amino salicylic acid
clarithromycin; AMX-CLA, amoxicillin b-lactam antibiotic with clavulan
a Capreomycin or viomycin may be used for kanamycin or amikacinTherapy regimens that include a new-generation FQ (MFX or
GFX), an injectable agent and bactericidal second-line
drugs with manageable side effects are associated with
better clinical outcome. Studies have also shown that
therapy with insufficient number of second-line drugs while
awaiting DST results may actually result in acquisition of
resistance to additional drugs.101,111
In addition to aggressive therapy with 5e7 drugs in initial
phase, other factors also influence rapid sputum conversion
and improve treatment outcome. These include therapy for
>3 months with 6 or more active drugs, use of an effective
injectable agent for >6 months, oral treatment for >18
months and initial resistance to fewer drugs.97,110,112 Regular
(once a month) monitoring of sputum specimens for smear
microscopy, culture and DST indicates response to treatment
and should be carried out until sputum culture conversion
has beenachieved. Early sputumculture conversion (within 2
months of initiating therapy) is associated with better clin-
ical outcome while patients who remain sputum culture-
positive at three months are more likely to have poor prog-
nosis.110,112 Continued sputum smear and culture positivity
without clinical improvement usually indicate ineffective
therapy or poor adherence to treatment and warrant fresh
DST and reassessment of treatment strategies.101,110
Directly observed therapy (DOT) support for MDR-TB
patients ensures adherence to treatment regimens and
rapid adjustments to avoid adverse drug reactions minimize
the risk of default. This is best achieved in hospital settings,
since inpatient management allows close monitoring for
adverse drug reactions and also ensures patient’s adher-
ence to treatment.113,114 However, recent studies have
shown that successful treatment of MDR-TB patients can
also be achieved in community settings even in developing
countries.115e117 Community-based treatment decreases
the chances for nosocomial transmission of infection to
other patients and health care workers.
The treatment of MDR-TB has been markedly less
successful in developing countries due to lack of rapid
diagnostic methods, universal culture and DST facilities andMDR-TB and XDR-TB.
Total duration of
treatment, months
Desirable number of
active drugs for
favorable outcome
6 4
6e9 4
9e12 4e5
18e24 5e6
18e24 5e6
24 5e7
24 5e7
>24 5e7
>24 5e7
>24 5e7
M, streptomycin; FQ, ciprofloxacin or ofloxacin or levofloxacin or
in or amikacin or capreomycin or viomycin; SLD, second-line drugs
, D-cycloserine and thiacetazone; TLD, third-line drugs like CLR,
ate b-lacatamase inhibitor; CFZ, clofazimine; and LZD, linezolid.
or vise versa if no cross-resistance is observed.
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under WHO’s DOTS strategy in endemic countries for MDR-
TB has been largely ineffective and has actually resulted in
emergence of additional resistance.95e97 The WHO and its
international partners have now evolved DOTS-Plus strategy
for better treatment of MDR-TB patients in developing
countries.118 The WHO’s Green Light Committee (GLC) has
subsidized drug prices but have also exerted strict control
on availability of second-line drugs. However, onlyw10% of
MDR-TB cases in developing countries are currently being
treated under the GLC program. Thus, greater distribution
of quality-assured drugs, universal culture and DST avail-
ability for initial diagnosis and for monitoring response to
therapy will be required to substantially decrease the
overall burden of MDR-TB in resource-poor settings.
Successful treatment of XDR-TB is much more difficult
than MDR-TB even in developed countries and involves
therapy with all available first-, second- and third-line
drugs, close monitoring of patients for adverse drug reac-
tions and other interventions such as surgery.93,94 In
developing countries, XDR-TB is virtually an untreatable
disease and all efforts should be made to minimize its
emergence by successful treatment of the existing MDR-TB
cases. Modeling studies have shown that emergence of XDR-
TB can be avoided by proper management of MDR-TB.17
However, treatment and management of MDR-TB can not be
accomplished without local laboratory capacity for sputum
culture, DST and close monitoring of patients for adherence
to treatment regimens and for adverse drug reactions.
Promising new anti-TB drugs
Rifampin was the last TB-specific drug introduced in
combination therapy regimens and was instrumental, due
to its activity against non-replicating persistent bacteria, in
reducing the duration of chemotherapy to six months which
has remained unchanged for nearly forty years.5,119 The
incomplete eradication of non-replicating persistent bacilli
is a major factor for relapse or treatment failure in TB
patients not adhering to therapy.119,120 To overcome this
phenotypic drug resistance, strict monitoring of treatment
under DOTS strategy with four first-line drugs for six months
was instituted. However, this labor-intensive strategy for
an extended period of time has been too difficult to
implement on a nationwide scale for many countries
resulting in development of drug-resistant and MDR M.
tuberculosis strains.1 The search for new anti-TB drugs aims
to shorten the treatment duration of drug sensitive active
TB to 2 months. Mathematical modeling studies have shownTable 5 Some promising anti-tubercular drugs in various stages
Potential drug Active or Pro-drug Description
PA-824 Pro-drug Nitroimidazo-oxazine
OPC-67683 Pro-drug Nitroimidazo-oxazole
R207910 Active Diarylquinoline
SQ109 Active Ethylenediamine derivat
Compound 5 Pro-drug Quinoxaline-oxide deriva
Compound 7 g Unknown Quinoline-isoxazole derivthat nearly a fourth of new TB cases and TB-related deaths
could be avoided with the introduction of a 2 month
regimen in South-Southeast Asia alone.121 The worldwide
emergence of MDR-TB and XDR-TB has also accelerated the
search for novel drugs against new targets that will be
effective against MDR and XDR M. tuberculosis strains.
New anti-TB drugs, to be effective, must have potency
greater than the most active drugs currently available
against actively dividing and non-replicating persistent
bacteria (exemplified by INH and RIF, respectively, in the
current treatment regimens). The substitution of EMB by
newer fluoroquinoloes (MXF and GFX) in the standard
treatment regimens shows promise to shorten the duration
of treatment from the current 6 months to 4 months.122
Several new anti-TB drugs (Table 5) are at various stages of
development for the treatment of drug sensitive active TB,
MDR-TB and XDR-TB.
The PA-824, a nitroimidazo-oxazine pro-drug of nitro-
imidazole class is a promising new compound and is
currently undergoing Phase II clinical trials for drug sensi-
tive TB.123,124 This drug requires bioreductive activation to
exert its antitubercular effect. The PA-824 is equally active
against drug sensitive as well as MDR M. tuberculosis strains
and is also active against non-replicating persistent
bacteria, making it an ideal drug candidate to shorten
treatment duration.123,124 The OPC-67683, a nitroimidazo-
oxazone pro-drug of nitroimidazole class is another prom-
ising new compound and is currently undergoing Phase II
clinical trials for the treatment of MDR-TB.125 Although
both PA-824 and OPC-67683 are activated by the same
mechanism, their cellular targets are different. In vitro
generated PA-824-resistant strains have identified
a conserved hypothetical protein (Rv3547) of M. tubercu-
losis as the main target of PA-824. Although the exact
function of the target protein is not known at present, the
PA-824-resistant M. tuberculosis strains with mutations in
Rv3547 remained sensitive to nitroimidazo-oxazines.126
The drug R207910 (also known as TMC207) is a diary-
lquinoline that inhibits adenosine triphosphate (ATP) syn-
thase.127 This novel compound has excellent activity
against both, drug sensitive as well as MDR M. tuberculosis
strains.128 In animal models, R207910 has shown more
potent early bactericidal activity than INH during early
phase of infection and higher bactericidal activity late in
infection than RIF alone.127 The activity of R207910 against
both, actively dividing and non-replicating persistent
bacteria suggests that this anti-TB drug also has great
potential to shorten the duration of treatment for drug
sensitive as well as MDR-TB.128 Phase II clinical trials areof development.
Cellular process inhibited Stage of development
Mycolic acid synthesis Phase II
Mycolic acid synthesis Phase II
ATP synthesis Phase II
ive Lipid/cell wall synthesis Phase I
tive Unidentified Preclinical
ative Unidentified Preclinical
1786 S. Ahmad, E. Mokaddascurrently being conducted to evaluate its safety and effi-
cacy in combination therapy with standardized second-line
treatment regimen for MDR-TB.
The 1,2-ethylenediamine (also known as SQ109) is
structurally related to first-line drug, EMB.129 However, its
mechanism of action appears to be different than that of
EMB as the drug has in vitro bactericidal activity against
EMB-resistant M. tuberculosis strains. The drug also
exhibits synergistic bactericidal action with INH and RIF and
has now entered phase I clinical trials for dose-dependant
efficacy studies.129,130
Several other new anti-TB drugs have also shown prom-
ising results for both, drug sensitive and drug-resistant
M. tuberculosis strains. Notable among these are compound
5, a quinoxaline-oxide derivative and compound 7 g,
a quinoline-isoxazole derivative (Table 5).131,132 Both drugs
have shown submicromolar and micromolar bactericidal
activities against actively dividing and non-replicating
persistent bacteria, respectively, under in vitro conditions.
If these findings are also replicated under in vivo condi-
tions, these drugs will add further to the promising leads for
new anti-TB drug development. Hopefully, some of these
drugs will be finally approved for the treatment and proper
management of MDR-TB.
Conclusion
The current MDR-TB epidemic is the result of decades of
neglect for an important infectious disease, lack of
resources for national TB control programs, poor case
detection and inadequate/inappropriate therapy in high-
burden countries. Initial outbreaks of MDR-TB in developed
countries were associated with very high mortality rates
both in HIV-negative and HIV-coinfected patients. Optimi-
zation of treatment regimens together with rapid diagnosis
and DST for first- and second-line drugs, greatly improved
the clinical outcome. Recent advances in diagnosis of MDR-
TB and aggressive empirical treatment of patients with
several drugs in the initial phase of treatment have further
improved the prognosis MDR-TB. However, in developing
countries, the prognosis is still largely poor due to inade-
quate laboratory support that is critical for successful
management of MDR-TB patients. Rapid and cost-effective
methods for culture and DST of M. tuberculosis strains have
recently been developed that are suitable for resource-
poor countries. The new anti-TB drugs that are in various
stages of development also offer hope that we will not soon
run out of treatment options against TB and MDR-TB.Acknowledgements
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